GSK plc (GSK,GSK.L) announced that its investigational B7-H3-targeted antibody-drug conjugate, GSK5764227 or GSK'227, has received Orphan Drug Designation from the European Medicines Agency (EMA). The designation is for the treatment of pulmonary neuroendocrine carcinoma (NEC), a rare and aggressive group of cancers that includes small-cell lung cancer (SCLC).
This is the fourth regulatory designation for GSK'227, exemplifying the potential of this targeted ADC, which is being developed in a range of solid tumour types, including in lung, prostate and colorectal cancers. Previously, GSK'227 was granted Priority Medicines (PRIME) designation by the EMA for relapsed or refractory ES-SCLC and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma granted by the US FDA.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.